Walleye Capital’s Vir Biotechnology VIR Stock Holding History

Walleye Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100	Closed	-$896	–	5195
2026 Q1	$896	Buy	+100	New	+$797	﹤0.01%	4265
2025 Q4	–	Sell	-10,600	Closed	-$60.5K	–	5177
2025 Q3	$60.5K	Sell	10,600 -2,300	-18%	-$11.8K	﹤0.01%	3932
2025 Q2	$65K	Buy	+12,900	New	+$69.2K	﹤0.01%	3947
2024 Q4	–	Sell	-4,400	Closed	-$33K	–	5606
2024 Q3	$33K	Buy	+4,400	New	+$38.2K	﹤0.01%	4725
2023 Q4	–	Sell	-4,000	Closed	-$37.5K	–	5564
2023 Q3	$37.5K	Sell	4,000 -13,300	-77%	-$190K	﹤0.01%	4264
2023 Q2	$424K	Sell	17,300 -2,500	-13%	-$62.8K	﹤0.01%	2556
2023 Q1	$461K	Buy	+19,800	New	+$506K	0.01%	1788

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Walleye Capital's VIR Position: Q2 2026 in Review

Walleye Capital reduced its Vir Biotechnology (VIR) stake by 23% in Q2 2026, selling an estimated $1.44M and leaving 514,251 shares worth $5.24M. The position accounts for 0.02% of the portfolio, ranked #800.

Walleye Capital first reported a position in VIR in Q4 2021 and has held it in 13 quarters since. The position peaked at $21.2M in Q2 2023. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Walleye Capital held 514,251 shares of Vir Biotechnology worth $5.24M as of Q2 2026.
Walleye Capital sold 151,333 Vir Biotechnology shares in Q2 2026, an estimated $1.44M.
Vir Biotechnology made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #800 holding.
Walleye Capital first reported a position in Vir Biotechnology in Q4 2021 and has held it in 13 quarters since.
Walleye Capital's Vir Biotechnology position peaked at $21.2M in Q2 2023.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.